[1] DiMasi, J. A., Grabowski, H. G., & Hansen, R. W., “Innovation in the pharmaceutical industry: New estimates of R&D costs.,” Journal of health economics, p. 20–33, 2016.
[2] Nosengo, N., “Can you teach old drugs new tricks?,” Nature, p. 314–316, 14 JUN 2016.
[3] Wang Fangfang, Mayca Pozo Franklin, Tian Danmei, Geng Xinran, Yao Xinsheng, Zhang Youwei, Tang Jinshan, “Shikonin Inhibits Cancer Through P21 Upregulation and Apoptosis Induction,” Frontiers in pharmacology, JUN 2020.
[4] Min Wang, Qilong Zhao,, “Electrospinning and Electrospray for Biomedical Applications,” Reference Module in Biomedical Sciences, pp. 330-344, 2019.
[5] A. M. Nikoo, R. Kadkhodaee, B. Ghorani, H. Razzaq, and N. Tucker,, “Electrospray-assisted encapsulation of caffeine in alginate microhydrogels,” Int J Biol Macromol, pp. 208-216, 2018.
[6] N. A. Brown, Y. Zhu, G. K. German, X. Yong, and P. R. Chiarot,, “Electrospray deposit structure of nanoparticle suspensions,” Journal of Electrostatics, pp. 67-73, DEC 2017.
[7] S. K. a. P. Biswas, “Electrospray deposition of biomolecules: Applications, challenges, and recommendations,” Journal of Aerosol Science, pp. 182-207, 2018.
[8] R. M. D. Soares, N. M. Siqueira, M. P. Prabhakaram, and S. Ramakrishna, “Electrospinning and electrospray of bio-based and natural polymers for biomaterials development,” Mater Sci Eng C Mater Biol Appl, pp. 969-982, 2018.
[9] Kamei N, Takeda-Morishita M, “Brain delivery of insulin boosted by intranasal coadministration with cell-penetrating peptides,” J Control Release, p. 105–110, 10 JAN 2015.
[10] Tarek M. Fahmy, Peter M. Fong, Amit Goyal, W. Mark Saltzman,, “Targeted for drug delivery,” Materials Today,, pp. 18-26, Aug 2005.
[11] Deng Yudi, Zhang Xudong, Shen Haibin, He Qiangnan, Wu Zijian, Liao Wenzhen, Yuan Miaomiao, “Application of the Nano-Drug Delivery System in Treatment of Cardiovascular Diseases,” Frontiers in Bioengineering and Biotechnology, p. 489, 2020.
[12] Bhagwat, R.R, & Vaidhya, I.S, “NOVEL DRUG DELIVERY SYSTEMS: AN OVERVIEW,” International Journal of Pharmaceutical Sciences and Research, pp. 970-982, 11 FEB 2013.
[13] P.D., Reddy., “Swarnalatha D.Recent advances in Novel Drug Delivery Systems,” IJPTR, pp. 2025-2027, NOV 2009.
[14] Huynh C.T., Lee D.S, Controlled Release, Springer, Berlin, Heidelberg: Encyclopedia of Polymeric Nanomaterials, 2015.
[15] Kesharwani, P., Gajbhiye, V., and Jain, N. K., “A review of nanocarriers for the delivery of small interfering RNA.,” Biomaterials 33, p. 7138–7150, 2012.
[16] Baeza, A., Ruiz-Molina, D., and Vallet-Regi, M., “Recent advances in porous nanoparticles for drug delivery in antitumoral applications: inorganic nanoparticles and nanoscale metal-organic frameworks.,” Expert Opin. Drug Deliv., p. 783–796, SEP 2016.
[17] Prijic, S., and Sersa, G., “Magnetic nanoparticles as targeted delivery systems in oncology. Radiol.,” Oncol., p. 1–16, MAR 2011.
[18] Hossen S, Hossain MK, Basher MK, Mia MNH, Rahman MT, Uddin MJ., “Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review,” J Adv Res., pp. 1-18, 25 JUN 2018.
[19] Nedal Y. Abu-Thabit, Abdel Salam H. Makhlouf, “1 - Historical development of drug delivery systems: From conventional macroscale to controlled, targeted, and responsive nanoscale systems,” Stimuli Responsive Polymeric Nanocarriers for Drug Delivery Applications, pp. 3-41, 2018.
[20] A.K. Bajpai, Sandeep K. Shukla, Smitha Bhanu, Sanjana Kankane,, “Responsive polymers in controlled drug delivery,” Progress in Polymer Science, pp. 1088-1118, NOV 2008.
[21] Ahirrao, S. P., Gide, P. S., Shrivastav, B., & Sharma, P., “Ionotropic Gelation: A Promising Cross Linking Technique for Hydrogels.,” Res Rev J Pharm Nanotechnol, pp. 1-6, MAR 2014.
[22] Smidsrod O, Skjak-Bræk G, “Alginate as immobilization matrix for cells,” Trend Biotechnol, p. 71–78, 1990.
[23] Tønnesen HH, Karlsen J., “Alginate in drug delivery systems,” Drug Dev Ind Pharm, pp. 621-630, 28 JUL 2002.
[24] Mooney, Kuen Yong Lee and David J., “Alginate: properties and biomedical applications,” Prog Polym Sci, p. 106–126, JAN 2012.
[25] Sneha Anand, P.S. Rajinikanth,, “ Alginate-based nanomaterials in drug delivery applications,” Biopolymer-Based Nanomaterials in Drug Delivery and Biomedical Applications, pp. 339-364, 2021.
[26] Ahirrao, S. P., Gide, P. S., Shrivastav, B., & Sharma, P., “Ionotropic Gelation: A Promising Cross Linking Technique for Hydrogels.,” Res Rev J Pharm Nanotechnol, pp. 1-6, MAR 2014.
[27] Grøndahl, L., Lawrie, G. and Jejurikar, A., “Alginate-based drug delivery devices.,” Biointegration of Medical Implant Materials, pp. 236-266, 2010.
[28] Krishnayan Haldar and Sudipto Chakraborty ,, “Investigation of chemical reaction during sodium alginate drop impact on calcium chloride film,” Physics of Fluids 31, 12 JUN 2019.
[29] Janja Mirtič, Janez Ilaš, Julijana Kristl,, “Influence of different classes of crosslinkers on alginate polyelectrolyte nanoparticle formation, thermodynamics and characteristics,” Carbohydrate Polymers, pp. 93-102, 2018.
[30] Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jemal,A., “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.,” CA Cancer J, p. 394–424, 12 SEP 2018.
[31] 國民健康署, "衛生福利部公布107年癌症發生資料," 國民健康署, 29 Dec 2020. [Online]. Available: https://www.mohw.gov.tw/cp-4624-57360-1.html. [Accessed 11 May 2021].
[32] Bethesda, MD,, "SEER Cancer Stat Facts: Ovarian Cancer.," National Cancer Institute, 2021. [Online]. Available: https://seer.cancer.gov/statfacts/html/ovary.html. [Accessed 11 MAY 2021].
[33] Novoa, Vargas Arturo, “Natural history of ovarian cancer. Ecancermedicalscience,” ecancer, pp. 465-465, 25 SEP 2014.
[34] K., Ushijima, “Treatment for recurrent ovarian cancer-at first relapse,” J Oncol, pp. 497429-497429, 24 Dec 2010.
[35] G. GH., “Management of relapsed ovarian cancer: a review. Springerplus,” Springerplus, pp. 1197-1197, 28 JUL 2016.
[36] Zhao Haiyun, Xu Fei, Li Jiajia, Ni Mengdong, Wu Xiaohua, “A Population-Based Study on Liver Metastases in Women With Newly Diagnosed Ovarian Cancer,” Frontiers in Oncology, 25 SEP 2020.
[37] Clarke-Pearson DL., "Clinical practice. Screening for ovarian cancer," The New England journal of medicine, vol. 361, no. 2, p. 170–177, 2009.
[38] D. A. M. A. Doubeni CA, “Diagnosis and Management of Ovarian Cancer.,” Am Fam Physician, pp. 937-44, JUN 2016.
[39] Nelson HD, et al. , “Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S,” Ann Intern Med., p. 255–266, 2014.
[40] Jayson, G. C., Kohn, E. C., Kitchener, H. C., and Ledermann, J. A., “Ovarian cancer,” 於 Lancet, 2014.
[41] M. Mara H Rendi, PhD, “Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Histopathology,” 2019..
[42] Romero I, Bast RC Jr., “Minireview: Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy,” Endocrinology., pp. 1593-1602, APR 2012.
[43] C. R. S. L. Christine Stewart, “Ovarian Cancer: An Integrated Review,” Semin Oncol Nurs, pp. 151-156, APR 2019.
[44] Moyer VA., “Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement,” Ann Intern Med., p. 900–904, 18 DEC 2012.
[45] Jacobs IJ, Menon U, Ryan A, et al., “Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial,” Lancet, pp. 2182-2193, 2015.
[46] Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS, “European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.,” N Engl J Med., pp. 943-953, 2 SEP 2010.
[47] Lim HJ, Ledger W., “Targeted therapy in ovarian cancer.,” Womens Health (Lond), pp. 363-378, 12 JUN 2016.
[48] Rockville (MD), Incorporating Alcohol Pharmacotherapies Into Medical Practice., US: Center for Substance Abuse Treatment., 2009, p. Chapter 3.
[49] Malin Wickström, Katarina Danielsson, Linda Rickardson, Joachim Gullbo, Peter Nygren, Anders Isaksson, Rolf Larsson, Henrik Lövborg,, “Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients,” Biochemical Pharmacology, pp. 25-33, JAN 2007.
[50] J. H. a. E. Jacobsen, “A drug sensitising the organism to ethyl alcohol,” The Lancet, pp. 1001-1004, 1948.
[51] K. Hochsattel and P. Brieger, “[Disulfiram in outpatient treatment of alcohol dependency],” Nervenarzt, p. 506–512, 2016.
[52] R. Beijersbergen, “New tricks for old drugs,” Nature Cancer, p. 153–155, JAN 2020.
[53] Pushpakom, S., Iorio, F., Eyers, P. et al.;, “Drug repurposing: progress, challenges and recommendations,” Nature Reviews Drug Discovery, p. 41–58, 2019.
[54] García-Serradilla M, Risco C, Pacheco B., “Drug repurposing for new, efficient, broad spectrum antivirals.,” Virus research, p. 22–31, FEB 2019.
[55] Jean-Pierre Jourdan, Ronan Bureau, Christophe Rochais, Patrick Dallemagne, “Drug repositioning: a brief overview,” Journal of Pharmacy and Pharmacology, p. 1145–1151, 9 SEP 2020.
[56] Monneret C, Bohuon C., Fabuleux hasards: histoire de la découverte de médicaments, Paris: EDP, 2009.
[57] Ashburn, T. T. & Thor, K. B., “Drug repositioning: identifying and developing new uses for existing drugs,” Nature Reviews Drug Discovery, p. 673–683, 01 AUG 2004.
[58] Wickström, M., Danielsson, K., Rickardson, L., Gullbo, J., Nygren, P., Isaksson, A., Larsson, R., & Lövborg, H., “Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients.,” Biochemical pharmacology, p. 25–33, 2007.
[59] Youssef A. Rezk, Kun Yang, Shoumei Bai, Karen Mclean, Carolyn Johnston, R. Kevin Reynolds, Ronald J. Buckanovich,, "Disulfiram’s Antineoplastic Effects on Ovarian Cancer," Journal of Cancer Therapy, vol. 6, no. 14, pp. 2151-1934, Dec 2015.
[60] Ronald Lindahl, “Aldehyde Dehydrogenases and Their Role in Carcinogenesis,” Critical Reviews in Biochemistry and Molecular Biology, pp. 283-335, 1992.
[61] Shen, M. L., Lipsky, J. J., & Naylor, S, “Role of disulfiram in the in vitro inhibition of rat liver mitochondrial aldehyde dehydrogenase.,” Biochemical pharmacology, p. 947–953, 2000.
[62] Brar, S. S., Grigg, C., Wilson, K. S., Holder, W. D., Jr, Dreau, D., Austin, C., Foster, M., Ghio, A. J., Whorton, A. R., Stowell, G. W., Whittall, L. B., Whittle, R. R., White, D. P., & Kennedy, T. P., “Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease.,” Molecular cancer therapeutics,, p. 1049–1060, 2004.
[63] Shian, S. G., Kao, Y. R., Wu, F. Y., & Wu, C. W., “Inhibition of invasion and angiogenesis by zinc-chelating agent disulfiram.,” Molecular pharmacology, p. 1076–1084, 2003.
[64] Lewis DJ, Deshmukh P, Tedstone AA, Tuna F, O'Brien P., “On the interaction of copper (II) with disulfiram,” Chem Commun 50, pp. 13334-13337, 2014.
[65] Hassani, S., Ghaffari, P., Chahardouli, B., Alimoghaddam, K., Ghavamzadeh, A., Alizadeh, S., & Ghaffari, S. H., “Disulfiram/copper causes ROS levels alteration, cell cycle inhibition, and apoptosis in acute myeloid leukaemia cell lines with modulation in the expression of related genes.,” Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, p. 561–569, 2018.
[66] Cen D, Gonzalez RI, Buckmeier JA, Kahlon RS, Tohidian NB, Meyskens FL Jr., “Disulfiram induces apoptosis in human melanoma cells: a redox-related process,” Mol Cancer Ther., pp. 197-204, 1 JAN 2002.
[67] Wang W, McLeod HL, Cassidy J., “Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines.,” Int J Cancer, p. 504–511, 20 APR 2003.
[68] Daniel KG, Chen D, Orlu S, Cui QC, Miller FR, Dou QP., “Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells,” Breast Cancer Res, p. 897–908, 2005.
[69] Horsman, M. R., Overgaard J, “Hyperthermia: a Potent Enhancer of Radiotherapy,” Clinical Oncology, pp. 418-426, AUG 2007.
[70] J., van der Zee, “Heating the patient: a promising approach?,” Annals of Oncology, p. 1173–1184, 2002.
[71] Issels R. D., “Hyperthermia adds to chemotherapy,” European journal of cancer, p. 2546–2554, 2008.
[72] Song CW et al., “Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment.,” Int J Hyperthermia, pp. 761-767, 2005.
[73] Jain RK., “Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.,” Science, pp. 58-62, 2005.
[74] Ahmed Bettaieb, Paulina K. Wrzal and Diana A. Averill-Bates, “Hyperthermia: Cancer Treatment and Beyond,” Open access peer-reviewed chapter, MAY 2013.
[75] Feldman AL, Libutti SK, Pingpank JF, et al., “Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.,” Journal of Clinical Oncology, p. 4560–4567, 2003.
[76] Chang E, Alexander HR, Libutti SK, et al., “Laparoscopic continuous hyperthermic peritoneal perfusion.,” Journal of the American College of Surgeons, p. 225–229, 2001.
[77] Kapp DS, Hahn GM, Carlson RW., Principles of Hyperthermia., Hamilton, Ontario: B.C. Decker Inc.: Bast RC Jr., Kufe DW, Pollock RE, et al., 2000.
[78] Wu W, Jiang CZ, Roy VAL., “Designed synthesis and surface engineering strategies of magnetic iron oxide nanoparticles for biomedical,” Nanoscale, p. 19421–19474, 2016.
[79] I. B. H. Y. Obaidat IM, “Magnetic properties of magnetic nanoparticles for efficient hyperthermia,” Nanomaterials, p. 63–89, 2015.
[80] Arruebo M, Fernandez-Pacheco R, Ibarra MR, Santamar ´ ´ıa J. M, “Magnetic nanoparticles for drug delivery,” Nano Today, pp. 22-32, JUN 2007.
[81] El-Boubbou K., “Magnetic iron oxide nanoparticles as drug,” Nanomedicine, pp. 953-971, JAN 2018.
[82] Sagratini, G., Cristalli, G., Giardinà, D., Gioventù, G., Maggi, F., Ricciutelli, M., & Vittori, S., “Alkannin/shikonin mixture from roots of Onosma echioides (L.) L.: extraction method study and quantification.,” Journal of separation science, p. 945–952, 2008.
[83] Information, ational Center for Biotechnology, "PubChem Compound Summary for CID 479503," Shikonin, 2004. [Online]. Available: https://pubchem.ncbi.nlm.nih.gov/compound/Shikonin.. [Accessed 6 APR 2021].
[84] Chen, X., Yang, L., Zhang, N., Turpin, J. A., Buckheit, R. W., Osterling, C, “Shikonin, a component of chinese herbal medicine, inhibits chemokine receptor function and suppresses human immunodeficiency virus type 1,” Antimicrob Agents Chemother, p. 199–209, SEP 2003.
[85] Li H, Tong Y, Bai L, Ye L, Zhong L, Duan X, Zhu Y. , “Lactoferrin functionalized PEG-PLGA nanoparticles of shikonin for brain targeting therapy of glioma.,” Int J Biol Macromol., pp. 204-211, Feb 2018.
[86] Chen J, Xie J, Jiang Z, Wang B, Wang Y, Hu X, “Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2,” Oncogene, pp. 4297-306, 20 OCT 2011.
[87] Nicholas Wong, Diane Ojo, Judy Yan, Damu Tang,, “PKM2 contributes to cancer metabolism,” Cancer Letters, pp. 184-191, 28 JAN 2015.
[88] Zahra Kulsoom, Dey Tulika, Ashish , Mishra Surendra Pratap, Pandey Uma, “Pyruvate Kinase M2 and Cancer: The Role of PKM2 in Promoting Tumorigenesis,” Frontiers in Oncology, 02 Mar 2020.
[89] Zahra K, Dey T, Ashish, Mishra SP, Pandey U, “Pyruvate Kinase M2 and Cancer: The Role of PKM2 in Promoting Tumorigenesis.,” Front Oncol, 2 Mar 2020.
[90] Institute, the National Cancer, "Sentinel Lymph Node Biopsy," the National Cancer Institute, 25 JUN 2019. [Online]. Available: https://www.cancer.gov/about-cancer/diagnosis-staging/staging/sentinel-node-biopsy-fact-sheet. [Accessed 05 APR 2021].
[91] Gould EA, Winship T, Philbin PH, Kerr HH, “ Observations on a “sentinel node” in cancer of the parotid,” Cancer, p. 77–78, 1960.
[92] Khoury-Collado F, Murray MP, Hensley ML, “Sentinel lymph node mapping for endometrial cancer improves the detection of metastatic disease to regional lymph nodes.,” Gynecol Oncol , p. 251–254, 2011.
[93] Renz M, Diver E, English D, et al., “Sentinel lymph node biopsies in endometrial cancer: Practice patterns among gynecologic oncologists in the United States.,” Journal of Minimally Invasive Gynecology, pp. 1553-4650, 10 APR 2019.
[94] Hoffman, M. S., Parsons, M., Gunasekaran, S., & Cavanagh, D., “ Distal external iliac lymph nodes in early cervical cancer.,” Obstetrics and gynecology, p. 391–394, 1999.
[95] Abu-Rustum, N. R., & Barakat, R. R., “Observations on the role of circumflex iliac node resection and the etiology of lower extremity lymphedema following pelvic lymphadenectomy for gynecologic malignancy.,” Gynecologic oncology, p. 4–5, JUL 2007.
[96] Grischke, E. M., Röhm, C., Hahn, M., Helms, G., Brucker, S., & Wallwiener, D., “ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes in Breast Cancer: Results of a Prospective Open-label Clinical Trial.,” Geburtshilfe und Frauenheilkunde, p. 935–940, SEP 2015.
[97] Pandit-Taskar, N., Gemignani, M. L., Lyall, A., Larson, S. M., Barakat, R. R., & Abu Rustum, N. R., “Single photon emission computed tomography SPECT-CT improves sentinel node detection and localization in cervical and uterine malignancy.,” Gynecologic oncology, p. 59–64, 2010.
[98] Jarmo T. Alander, Ilkka Kaartinen, Aki Laakso, Tommi Pätilä, Thomas Spillmann, Valery V. Tuchin, Maarit Venermo, Petri Välisuo, “A Review of Indocyanine Green Fluorescent Imaging in Surgery,” International Journal of Biomedical Imaging, 22 APR 2012.
[99] G. W. P. J. A. J. P. M. F. A. e. a. How J, “Comparing indocyanine green, technetium, and blue dye for sentinel lymph node mapping in endometrial cancer. Gynecol Oncol.,” Gynecol Oncol., p. 436–442, JUN 2015.
[100] Van den Berg NS, van Leeuwen FW, van der Poel HG., “Fluorescence guidance in urologic surgery,” Curr Opin Urol., p. 109–120., 2012.
[101] Smith BAJ, Fader AN, Tanner EJ., “Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis,” Am J Obstet Gynecol., p. 459–476, MAY 2017.
[102] Nadeem R. Abu-Rustum MD, “Sentinel Lymph Node Mapping for Endometrial Cancer: A Modern Approach to Surgical Staging,” J Natl Compr Canc Netw, p. 288–297, 12 FEB 2014.
[103] Yuqing Wu, Jibo Jing, Jinfeng Wang, Bin Xu, Mulong Du and Ming Chen, “Robotic-Assisted Sentinel Lymph Node Mapping With Indocyanine Green in Pelvic Malignancies: A Systematic Review and Meta-Analysis,” Frontiers in Oncology , 2 Jul 2019.
[104] Aboumarzouk OM, Bondad J, Ahmed K, Khan MS, Kynaston HG,Dasgupta P, et al. , “Robotic versus open radical cystectomy for bladder cancer in adult,” Cochrane Database System Rev Ltd., 24 APR 2015.
[105] Cela V, Sergiampietri C, Rosa Obino ME, Bifulco G, Giovanni Artini P, Papini F., “Sentinel-lymph-node mapping with indocyanine green in robotic-assisted laparoscopic surgery for early endometrial cancer: a retrospective analysis.,” Facts Views Vis Obgyn., pp. 323-328, 4 NOV 2020.
[106] Intuitive Surgical, "Da Vinci Surgical Systems," Intuitive Surgical, 2020. [Online]. Available: https://www.intuitive.com/en-us/products-and-services/da-vinci/systems.
[107] Alessandri F, Tantari M, Barra F, Vellone VG, Gustavino C, Ferrero S , Centurioni MG, “Images from sentinel lymph node mapping with nearinfrared fluorescence during robot-assisted laparoscopic hysterectomy for suspicious of cervical cancer.,” Surg Rehabil., pp. 1-2, Oct 2018.
[108] L. Chan, "How to count cells using a hemocytometer," Nexcelom Bioscience LLC, June 2020. [Online]. Available: https://www.nexcelom.com/how-to-count-cells-using-a-hemacytometer/. [Accessed 14 APR 2021].
[109] A. B.-C. M. C. R. W. H. a. A. V. J. C. Stockert, “MTT assay for cell viability: Intracellular localization of the formazan product is in lipid droplets,” Acta Histochem, pp. 785-796, 2012.
[110] 陳旭心, “包覆雙硫侖與超順磁性氧化鐵海藻膠微米粒子的製備及其對卵巢癌細胞溫熱化學治療成效評估,” 於 國立臺灣科技大學醫學工程研究所碩士論文, 台北市, 2019.
[111] Albarqi HA, Wong LH, Schumann C, et al., “Biocompatible Nanoclusters with High Heating Efficiency for Systemically Delivered Magnetic Hyperthermia,” ACS Nano, pp. 6383-6395, JUN 2019.
[112] Yanfei Li, Junwei Shen, Ming Fang, Xiaoliu Huang, Hongwei Yan, Yueling Jin, Jue Li, Xinming Li,, “The promising antitumour drug disulfiram inhibits viability and induces apoptosis in cardiomyocytes,” Biomedicine & Pharmacotherapy, pp. 1062-1069, DEC 2018.
[113] 黃田碩, “紫草素可抑制卵巢癌細胞的生長和干擾其醣解代謝,” 於 國防醫學院病理及寄生蟲學研究所碩士論文, MAY, 2013.
[114] Landesman-Milo, D., Goldsmith, M., Leviatan, B. S., Witenberg, B., Brown, E., Leibovitch, S., et al., “ Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells.,” Cancer Lett., p. 221–227, 2013.
[115] Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S. et al., “Liposome: classification, preparation, and applications,” Nanoscale Res Lett, p. 102, 22 FEB 2013.